Japan Approves First iPS-Cell Therapies for Heart Failure and Parkinson’s
Japan’s health ministry conditionally approved two therapies derived from reprogrammed iPS cells—ReHeart for severe heart failure and Amusepri for Parkinson’s—marking the first medical treatments of this kind and signaling a new era in regenerative medicine, though extended safety and efficacy data from more patients are still needed.